Companies Developing Diabetes Treatments Forced To Get Creative In Crowded Field
"It’s not just sufficient any longer to have the best insulin,” Stefan Oelrich, head of Sanofi’s global diabetes franchise, says. “You have to go beyond that." Sanofi is launching a collaboration with Alphabet to research diabetes treatments.
Bloomberg:
Pills And Pens Bring Hope For Drug Companies In Diabetes Crunch
Novo Nordisk A/S, the industry’s biggest player, is investing in diabetes drugs that can be given as a pill rather than by injection, while Sanofi and Google parent Alphabet Inc. are committing about $500 million to a venture aimed at combining software and medicine to help patients manage the disease. Researchers elsewhere are working on the first artificial pancreas to take over for the malfunctioning organ and “smart patches” to deliver insulin patients need to keep sugar from pooling in their blood. (Paton, 9/12)
The Wall Street Journal:
Google Parent And Sanofi Name Diabetes Joint Venture Onduo
French pharmaceutical group Sanofi SA is joining with Verily Life Sciences LLC, a unit of Google parent Alphabet, to create a joint venture called Onduo to research diabetes treatments.“ Onduo’s mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management,” Sanofi and Verily, which was previously known as Google Life Science, said. (Landauro, 9/12)
